TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00662116
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets - two tablets taken twice daily
Study: NCT00280033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo.
Study: NCT03329443
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: each patient will receive 200 mg of spironolactone as per his/her angiography premedications
Study: NCT03329443
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive a placebo tablet as per his/her angiography premedications
Study: NCT00309556
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 cycles 1000mg/m2 oral, day 1-14 q2d
Study: NCT03136263
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intranasal placebo (inactive ingredients of Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
Study: NCT04674657
Drug: blood drug concentration
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: blood drug concentration
Study: NCT02221388
Drug: BI 671800 HEA, 200 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02221388
Drug: BI 671800 HEA EC, 200 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02221388
Drug: BI 671800 HEA, 50 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02221388
Drug: BI 671800 ED, 100 mg capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01280591
Drug: Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received two Naproxen sodium 220 mg / DPH (Diphenhydramine hydrochloride) 25 mg tablets orally, single dose
Study: NCT01280591
Drug: Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received one Naproxen sodium 220 mg / DPH 50 mg tablet and one matching placebo capsule orally, single dose
Study: NCT01280591
Drug: Naproxen sodium 440 mg (BAYH6689)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received two Naproxen sodium 220 mg tablets orally, single dose
Study: NCT01280591
Drug: DPH 50 mg
Normalized name: DPH 50 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received two DPH (Diphenhydramine hydrochloride) 25mg tablets orally, single dose
Study: NCT02321306
Drug: LUM001
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUM001 administered orally once each day.
Study: NCT01996085
Drug: Indapamide/hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. hypervolemic profile (man - TFC \> 34 1/kOhm; women - TFC \> 24 1/kOhm)~2. hyperconstrictive profile (SVRI \> 2500-2800 dyn•s•cm-5•m2) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with lisinopril/telmisartan)
Study: NCT01996085
Drug: Indapamide/hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug choice at the discretion of physician (blinded to ICG)
Study: NCT02720406
Drug: saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9% given by nebulizer before anesthesia and iv after anesthesia and before surgery.
Study: NCT02454543
Drug: Best systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the antiandrogenic therapy a non-steroidal antiandrogen (e.g. flutamide, bicalutamide) or a gonadotropin-releasing hormone (GnRH) analogues (e.g. goserelin, leuprolide) are available.~The selection of best systemic therapy is up to the judgment of the treating urologist.
Study: NCT01971385
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01546688
Drug: Placebo administered to match targeted daily doses of 100-500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT01178203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01178203
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tab, 500 mg in 6, 12, and 24 hours after root canal treatment
Study: NCT03120715
Drug: Low Molecular Weight Heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the endometrial thickness is greater than 9 mm, hCG 10000 IU will be administered via intramuscular injection.And low molecular weight heparin (LMWH) will be injected subcutaneously 4100 IU (WHO) every other day before FET.Then on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
Study: NCT03543137
Drug: Nicorette Mini Lozenge
Normalized name: Nicorette Lozenge Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of a 4 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
Study: NCT04027322
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for the control group.
Study: NCT01928511
Drug: Nucleos(t)ide analogue therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00202956
Drug: Bugusan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00349778
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide as a white powder in 100 mg, 200 mg and 500 mg vials, to be dissolved in \~250 mL of saline or D5W and infused IV over 2 hours
Study: NCT02602054
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Indomethacin:~Administer 1 full cycle (3 doses) / (1 dose every 12 hours) in the first fourteen days of life:~Preterm infants less than 48 hours of life: first dose 0.2 mg/kg, second dose 0.1 mg/kg and third dose 0.1 mg/kg Preterm infants more than 48 hours of life: first dose 0.2 mg/kg, second dose 0.2 mg/kg and third dose 0.2 mg/kg And preterm infants more than 7 days of life: first dose 0.2 mg/kg, second dose 0.25 mg/kg and third dose 0.25 mg/kg - Ibuprofen:~Administer 1 full cycle (3 doses) / (1 dose every 24 hours) in the first fourteen days of life of preterm infants:~First dose 10 mg/kg Second dose 05 mg/kg Third dose 05 mg/kg~- Acetaminophen~Administer 1 full cycle, in the first fourteen days of life in preterm infants:~Acetaminophen 15 mg/kg every 6 hours for 3 days
Study: NCT01821703
Drug: LY3045697
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as oral solution
Study: NCT01821703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as oral solution
Study: NCT01821703
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as capsule
Study: NCT01821703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as capsule
Study: NCT00881816
Drug: Liposomal paclitaxel plus capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All Patients will receive liposomal paclitaxel (with a dose of 60mg/m2,3h,ivgtt,at d1,8,15) and capecitabine (with a dose of 1600mg/m2,bid,po.,at d1-14),each cycle for 4 cycles.
Study: NCT02790684
Drug: DS-8500a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00367835
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00470925
Drug: 123-I MZINT injection and SPECT imaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI
Study: NCT01372410
Drug: GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mcg once daily
Study: NCT01372410
Drug: GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: 62.5 mcg once daily
Study: NCT01372410
Drug: GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: 31.25 mcg once daily
Study: NCT01372410
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once or twice daily
Study: NCT04496063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous followed by Placebo subcutaneous every 8 weeks
Study: NCT01560689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day, every day
Study: NCT02914691
Drug: Placebo identical once daily tablet treatment
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00742573
Drug: Antidepressants through Texas Medication Algorithm (TMA)
Normalized name: influenza A virus A/Texas/50/2012 (H3N2) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.
Study: NCT02552277
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo administered on study days 1, 29, and 57.
Study: NCT01270789
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo administered as once daily sc injection
Study: NCT02271997
Drug: Iron(III)carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: treatment with Iron(III)carboxymaltose and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
Study: NCT00389233
Drug: Macrogol3350 NA sulphate NACl KCl ascorbic acid NA ascorbate
Normalized name: ascorbic acid / polyethylene glycol 3350 / potassium chloride / sodium ascorbate / sodium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pack will consist of 2L NRL 994 - 4 (2 x PEG + E/P + 2 x Vitamin C/C) sachets for the 2L of 2 sachets (1 x P plus 1 x C) will be dissolved in 1L of water. Each litre will be drunk within 1 hour followed by at least 500ml of any additional clear fluid.
Study: NCT00037791
Drug: (PN-152,243)/PN-196,444
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00285402
Drug: AST-726 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03622853
Drug: Steroid (shincort)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intraarticular shincort 40mg / 4ml mixed with 2% xylocaine and Normal saline
Study: NCT01067326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill per day by mouth for 4 months
Study: NCT03441984
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRIUMEQ (Adult) administered as a, single dose, fixed dose combination (FDC) tablet - DTG 50 mg/ABC 600 mg/3TC 300 mg as 1 conventional tablet, orally as direct-to-mouth.
Study: NCT03441984
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRIUMEQ (Pediatric) administered as a, single dose, FDC tablet - DTG 5 mg/ABC 60 mg/ 3TC 30 mg, orally as 10 dispersible tablets
Study: NCT01222637
Drug: CetuGEX™
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04101708
Drug: Lansoprazole, Amoxicillin,Clarithromycin and Bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: half-dose clarithromycin-containing bismuth quadruple regimen
Study: NCT02962336
Drug: Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, crossover
Study: NCT02962336
Drug: Tribenzor Tablets of Daichi Sankyo Inc, USA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, crossover
Study: NCT00116740
Drug: APD356
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04757532
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of chlorthalidone (1 tablet) administered orally in a single dose.
Study: NCT02205931
Drug: Antiepileptic drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control intervention will be drug therapy with the most appropriate further antiepileptic drug for a particular child, depending on their presenting seizures and syndrome and previous drugs used, and chosen by the expert clinician responsible for management of the patient's epilepsy.
Study: NCT01968070
Drug: LY3127760
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01968070
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01968070
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01597518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2x in first 24 hours; Placebo 2x day 2--14
Study: NCT03452306
Drug: Glucophage® Long
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second Intervention Period:~Single administered dose of Glucophage® (750 mg tablet extended-release) in a fasting condition
Study: NCT03452306
Drug: Glucophage® Long
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fourth Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition
Study: NCT04140058
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of 10 mL normal saline was administered.
Study: NCT01624636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00801398
Drug: Oxymorphone IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label, 2 part, ascending dose, single and multiple dose q4-6 hrs up to 48 hrs
Study: NCT00373178
Drug: Anti-diabetic medications
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01670019
Drug: Placebo 1-4 tablets daily
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo tablet QHS, or one placebo tablet BID, or one placebo tablet QAM and two placebo tablets QHS, or two placebo tablets BID
Study: NCT03045042
Drug: Enzyme Replacement Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated following the decision of their doctors. The investigators are going to analyze serum samples of these patients
Study: NCT00796120
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 60 or 75 mg/m\^2 will be given intravenously every 3 weeks until disease progression.
Study: NCT02622230
Drug: Mianhuahua Flavonoids Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolerability Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(seven dose groups:0.3g-5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(six dose groups: 0.9g, 1.8g, 2.7g, 3.6g, 4.5g, 5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)
Study: NCT02622230
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match with experimental groups
Study: NCT02949089
Drug: ACH04
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects will receive the study medication in each group
Study: NCT01562951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLACEBO at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly
Study: NCT01677351
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03328533
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine bitartrate variable infusion with a starting rate of 0.1 mcg/Kg/min (equivalent to norepinephrine base of 0.05 mcg/Kg/min).
Study: NCT00145925
Drug: Perindopril-indapamide
Normalized name: indapamide / perindopril
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02232763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 weeks of losartan or placebo with crossover to the other
Study: NCT02938650
Drug: Nitrosomonas eutropha
Normalized name: Jatropha curcas seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will get nitrosomonas eutropha to apply for one week. There is only one arm to this study. Subjects will apply the medication twice a day for one week.
Study: NCT00571805
Drug: varencline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/day varencline (1.0 mg BID)
Study: NCT00571805
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT04371601
Drug: hormones
Normalized name: Other hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: a moderate amount of hormone
Study: NCT03618472
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch based placebo manufatured to mimic Metformin 850 mg
Study: NCT01169935
Drug: Administration of intra-dermal Endorem
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, intradermal
Study: NCT03959098
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
Study: NCT01093534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching solifenacin placebo tablet
Study: NCT00662779
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo dry powder capsules ( lactose) and placebo normal saline for nebulization
Study: NCT02164266
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo daily oral administration
Study: NCT02164266
Drug: RO6799477
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral administration of RO6799477
Study: NCT00860821
Drug: AZD8309
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution 30 mg/g, dose: 300mg bid for 3 days
Study: NCT04563000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,9 % solution of sodium chloride 100 ml intravenously every 12-hours for 4 consecutive days
Study: NCT01868451
Drug: Doxorubicin HCL
Normalized name: doxorubicin HCl
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01786239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The total daily dose for subjects assigned to placebo will be 2000 mg. This dose will start on day 1 and stay the same dose until study completion.
Study: NCT00611195
Drug: propofol, remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol 3micrgr/ml (TCI plasma concentration Kataria model) versus propofol 3micrgr/ml and remifentanil 0.05microgr/kg/min
Study: NCT03990038
Drug: Extended Release Capsule
Normalized name: 24 Hour Extended Release Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C receives a placebo for extended release hydromorphone Group U receives Hydromorph Contin 3 mg PO BID~See arm description
Study: NCT03706950
Drug: Elpida® + 2 NRTIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elpida® 20mg qd orally + 2 NRTIs standard prescribed ART therapy
Study: NCT02749656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: apply on the scalp psoriasis lesion twice a day
Study: NCT01298518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo giving for 4 weeks
Study: NCT03125213
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Match AL-3778 tablet
Study: NCT00081874
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: Starting dose 5 mg by mouth daily for 28 days.~Phase II: Maximum Tolerated Dose (MTD) from Phase I.
Study: NCT02447757
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil analgesia during delivery
Study: NCT01798277
Drug: Medical therapy (sotalol or amiodarone)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be tiered to one of two possible antiarrhythmic drugs (sotalol or amiodarone).
Study: NCT02211352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
Study: NCT03471871
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HV: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off).
Study: NCT04221035
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg/m2/dose
Study: NCT03471871
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.